|
The device was not returned for analysis.Production record and corrective and preventative actions (capa) reviews were performed and revealed no indication of a product quality issue.Additionally, a query of the complaint handling database for the reported lot revealed there is no indication of a lot specific issue.The reported patient effect of occlusion is listed in the esprit btk everolimus eluting resorbable scaffold systems instructions for use as a known patient effect of coronary stenting procedures.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling; therefore, no product-related corrective action will be implemented in this case.
|
|
Patient id: (b)(6).It was reported that on (b)(6) 2025, one 3.5x38 mm esprit btk was implanted in the heavily calcified, right proximal posterior tibial artery.On (b)(6) 2025 the patient was noted to have a new wound and a new occlusion in the posterior tibial artery.Revascularization of the target limb was performed on (b)(6) 2025 with 0% residual occlusion.No additional information was provided.
|